Literature DB >> 20425173

Exercise (18)FDG imaging for the detection of CAD: What are the clinical hurdles?

Diwakar Jain1, Zuo-Xiang He, Afshin Ghanbarinia.   

Abstract

Myocardial perfusion imaging (MPI) has been in clinical use for over 30 years, providing an effective, reliable, and relatively simple tool for diagnosis, risk stratification, and follow-up of patients with suspected or know coronary artery disease (CAD). The unique strength of nuclear imaging is its ability to provide tools for imaging biochemical and metabolic processes, and receptor and transporter functions at molecular and cellular levels in intact organisms under various physiologic conditions. Metabolic imaging using radiolabeled glucose analogues ((18)F-fluorodeoxyglucose [(18)FDG]) provides a unique ability to image myocardial ischemia directly ("hot spot" imaging) in patients with known or suspected CAD. Exercise (18)FDG imaging can potentially overcome some of the limitations of currently used stress-rest MPI. In this article, we describe recent studies using exercise (18)FDG for imaging myocardial ischemia and its potential use in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425173     DOI: 10.1007/s11886-010-0087-8

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  35 in total

Review 1.  Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease.

Authors:  G A Beller; B L Zaret
Journal:  Circulation       Date:  2000-03-28       Impact factor: 29.690

2.  Pursuit of the ideal perfusion agent.

Authors:  Barry L Zaret
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

Review 3.  Imaging of myocardial metabolism.

Authors:  Pilar Herrero; Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2005 May-Jun       Impact factor: 5.952

4.  18F-FDG uptake as a surrogate marker for antecedent ischemia.

Authors:  Vasken Dilsizian
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

Review 5.  Myocardial utilization of carbohydrate and lipids.

Authors:  J R Neely; M J Rovetto; J F Oram
Journal:  Prog Cardiovasc Dis       Date:  1972 Nov-Dec       Impact factor: 8.194

6.  Noninvasive regional myocardial perfusion with radioactive potassium. Study of patients at rest, with exercise and during angina pectoris.

Authors:  B L Zaret; H W Strauss; N D Martin; H P Wells; M D Flamm
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

7.  [18F]Fluorodeoxyglucose as a memory marker of transient myocardial ischaemia.

Authors:  Brian G Abbott; Yi-Hwa Liu; James A Arrighi
Journal:  Nucl Med Commun       Date:  2007-02       Impact factor: 1.690

Review 8.  Management of chronic coronary disease: is the pendulum returning to equipoise?

Authors:  William E Boden
Journal:  Am J Cardiol       Date:  2008-05-22       Impact factor: 2.778

9.  Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model.

Authors:  M Schwaiger; H R Schelbert; D Ellison; H Hansen; L Yeatman; J Vinten-Johansen; C Selin; J Barrio; M E Phelps
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

Review 10.  Fluorine 18-labeled fluorodeoxyglucose myocardial single-photon emission computed tomography: an alternative for determining myocardial viability.

Authors:  M P Sandler; J A Patton
Journal:  J Nucl Cardiol       Date:  1996 Jul-Aug       Impact factor: 5.952

View more
  2 in total

1.  Comparison of Tc-99m tetrofosmin myocardial perfusion scintigraphy and exercise F18-FDG imaging in detection of myocardial ischemia in patients with coronary artery disease.

Authors:  Sasikumar Arun; Bhagwant Rai Mittal; Anish Bhattacharya; Manoj Kumar Rohit
Journal:  J Nucl Cardiol       Date:  2014-08-15       Impact factor: 5.952

2.  Direct myocardial ischemia imaging with exercise ¹⁸FDG.

Authors:  Diwakar Jain; Zuo-Xiang He
Journal:  J Nucl Cardiol       Date:  2015-02       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.